Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Jian-Guo ZhouAnna-Jasmina DonaubauerBenjamin FreyIna BeckerSandra RutznerMarkus EcksteinRoger SunHu MaPhilipp SchubertClaudia SchweizerRainer FietkauEric DeutschUdo S GaiplMarkus HechtPublished in: Journal for immunotherapy of cancer (2022)
NCT03453892.